Applied UV Sign Exclusive Distribution Agreement with Vietnam Distributor for Airocide(R) Air Purification Systems
Applied UV, Inc. (AUVI) announced an exclusive distribution agreement with Viet My Instrument and Technology Joint Stock Company for Airocide® air purification systems in Vietnam. The distributor commits to purchasing at least 100 consumer and 45 commercial systems in the first year. As Vietnam's healthcare spending is projected to grow significantly, Applied UV aims to expand its presence in this high-growth market. The Airocide® technology is known for its effectiveness in eliminating airborne pathogens and has applications in various sectors such as healthcare and hospitality.
- Signing of an exclusive distribution agreement expected to enhance market presence in Vietnam.
- Distributor committed to a purchase of at least 145 Airocide® systems in the first year.
- Vietnam's projected healthcare expenditure growth offers a significant market opportunity.
- None.
Distributor will provide fast access to a high growth market
MOUNT VERNON, NY / ACCESSWIRE / June 3, 2021 / Applied UV, Inc. (NASDAQ:AUVI) ("Applied UV" or the "Company"), an infection control technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, today announced that today announced the signing of an exclusive distribution agreement with Viet My Instrument and Technology Joint Stock Company ("Distributor") for the distribution of the Airocide® consumer and commercial air purification systems in Vietnam.
Under the terms of the agreement, the Distributor has agreed to a purchase commitment of a minimum of 100 Consumer and 45 Commercial Airocide® systems over the initial one-year term of the agreement.
Vietnam offers manufacturers an exciting growth opportunity as the nearly 100-million-person country looks to upgrade their healthcare infrastructure in the coming decade. In 2019, total healthcare expenditure was estimated to be US
"Our strategy to expand our international presence by establishing relationships with high quality distributors continues to gain momentum ," said Q Saeed, CEO of Applied UV. "Over the last six months, we have created a distributor network to serve the Middle East, Africa, South America and now the country of Vietnam. We expect additional distributor relationships will be forged with other countries in Asia and throughout the world as we seek to rapidly grow our market share in the air and surface infection control market."
Airocide® System
The Airocide® System, originally developed by NASA with assistance from the University of Wisconsin at Madison, is an airborne pathogen killing technology that uses a patented combination of UVC and a proprietary, titanium dioxide based photocatalyst. Listed as an FDA Class II Medical device, the Airocide® technology is clinically proven and field tested to kill/remove/eliminate airborne pathogenic and non-pathogenic microorganisms, allergens, odors and harmful VOCs in a variety of applications and industries including healthcare, hospitality, grocery chains, wineries, commercial real estate, schools, dental offices and homes. Airocide® air purifiers are available at www.airocide.com.
About Applied UV
Applied UV is focused on the development and acquisition of technology that address infection control in the healthcare, hospitality, commercial and municipal markets. The Company has two wholly owned subsidiaries - SteriLumen, Inc. ("SteriLumen") and Munn Works, LLC ("Munn Works"). SteriLumen's connected platform for Data Driven Disinfection™ applies the power of ultraviolet light (UVC) to destroy pathogens safely, thoroughly, and automatically, addressing the challenge of healthcare-acquired infections ("HAIs"). Targeted for use in facilities that have high customer turnover such as hospitals, hotels, commercial facilities, and other public spaces, the Company's Lumicide™ platform uses UVC LEDs in several patented designs for infection control in and around high-traffic areas, including sinks and restrooms, killing bacteria, viruses, and other pathogens residing on hard surfaces within devices' proximity. The Company's patented in-drain disinfection device, Lumicide Drain, is the only product on the market that addresses this critical pathogen intensive location. SteriLumen's Airocide® products for air purification, developed by NASA and FDA Cleared as class II medical devices, utilize a proprietary photo-catalytic bioconversion technology that draws air into a reaction chamber that converts damaging molds, microorganisms, dangerous pathogens, destructive VOCs and biological gasses into harmless water vapor without producing ozone or other harmful byproducts. Airocide® applications include healthcare, hospitality, grocery chains, wine making facilities, commercial real estate, schools, dental offices, and homes.
For more information about Applied UV, Inc., and its subsidiaries, please visit the following websites: https://www.applieduvinc.com/; https://sterilumen.com/; and, https://munnworks.com/.
Forward-Looking Statements
The information contained herein may contain "forward‐looking statements." Forward‐looking statements reflect the current view about future events. When used in this press release, the words "anticipate," "believe," "estimate," "expect," "future," "intend," "plan," or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Such statements include, but are not limited to, statements contained in this press release relating to the view of management of Applied UV concerning its business strategy, future operating results and liquidity and capital resources outlook. Forward‐looking statements are based on the Company's current expectations and assumptions regarding its business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. The Company's actual results may differ materially from those contemplated by the forward‐looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward‐looking statements. Factors or events that could cause the Company's actual results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company cannot guarantee future results, levels of activity, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward‐looking statements to conform these statements to actual results.
Applied UV Investor Relations
TraDigital IR
Kevin McGrath
TraDigital IR
+1-646-418-7002
kevin@tradigitalir.com
SOURCE: Applied UV, Inc.
View source version on accesswire.com:
https://www.accesswire.com/650164/Applied-UV-Sign-Exclusive-Distribution-Agreement-with-Vietnam-Distributor-for-AirocideR-Air-Purification-Systems
FAQ
What recent agreement did Applied UV (AUVI) announce?
How many Airocide® systems will be purchased under the new agreement?
What is the significance of Vietnam's healthcare market for Applied UV?
What is the Airocide® system used for?
When was the distribution agreement with Viet My signed?
